New Preclinical Data Presented at SITC Annual Meeting Highlight Bavituximab’s Enhanced Anti-Tumor Activity When Combined With Checkpoint Inhibitors in Breast Cancer and Melanoma

Source: Globe Newswire, November 2015

Bavituximab in Combination with Anti-PD-1 in Breast Cancer Studies Showed a Statistically Significant Improvement in Overall Survival as Compared to Subjects Receiving Anti-PD-1 Therapy Alone –

– New Custom-Designed Immuno-Profiling Clinical Test Provides Further Evidence of Bavituxmab’s Immune Modulating Mechanism of Action in the Tumor Microenvironment –

TUSTIN, Calif., Nov. 09, 2015 (GLOBE NEWSWIRE) — Peregrine Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing therapeutics to stimulate the body’s immune system to fight cancer, today announced results from multiple new preclinical studies demonstrating enhanced anti-tumor activity and immune activation for combinations of a preclinical bavituximab equivalent and checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4 in preclinical models of breast cancer and melanoma.  Additionally, the company announced preliminary results for a new clinical test specifically designed to illustrate how bavituximab, the company’s investigational phosphatidylserine (PS)-signaling pathway inhibitor, modulates immune responses in the tumor microenvironment.  Results from these studies were presented at the 2015 annual meeting of the Society for Immunotherapy of Cancer (SITC), which was held in National Harbor, MD, on November 4 – 8, 2015.